Skye Bioscience is rated Buy, driven by nimacimab’s strong safety, durable weight-loss profile, and upcoming Phase 2a results. SKYE’s nimacimab targets the expanding anti-obesity market, showing ...
Eli Lilly (LLY) shares traded flat on Thursday as J.P. Morgan argued that adverse events overshadowed a potentially best-in-class weight loss profile indicated for its next-gen obesity therapy, ...
MSN: Eli Lilly confirms 'superior weight loss' of its next-generation obesity drug
Eli LillyLLY reported late-stage study results Thursday that confirmed the "superior weight loss profile" of its next-generation obesity treatment, retatrutide. On average, diabetic patients taking a ...